PSI Investigator Professor Sassy Molyneux has received a prestigious five-year NIHR Global Health Research Professorship. This award, granted to only five distinguished scientists annually, will support Professor Molyneux\u2019s research on protecting frontline staff from moral distress.
Researchers analysing data from mobile phone apps used during the COVID-19 pandemic found that digital contact tracing can help public health bodies to better monitor and analyse evolving epidemics.
PSI scientists are launching a new computer simulations project to model vaccine clinical trial designs and strengthen global response to pandemic threats.
Published in the journal Public Health Ethics, the research introduces an ethical framework for assessing the use of coercive antimicrobial stewardship policies to address the \u2018silent pandemic\u2019 of antimicrobial resistance.
A randomised controlled trial to evaluate the efficacy and safety of treatments for bubonic plague has enrolled over 220 patients in Madagascar, marking a critical milestone in evidence generation for plague treatments.
The Pandemic Sciences Institute, in collaboration with the global coalition of health research funders GloPID-R and UKCDR, has launched a new research programme including an interactive platform to track and analyse over $7 billion in global pandemic research funding.
A new study \u2013 led by researchers at PSI \u2013 has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more. The findings have been published today in the journal Nature.
Using data from 7 million people notified by the NHS COVID-19 contact tracing app, this is the first large-scale study to reveal how duration and proximity of contact with an infected person affects how COVID-19 is spread.
New University of Oxford research brings to light important ethical considerations in Nipah virus outbreak control, its treatment, and research into vaccines.
PSI has joined forces with the Science for Africa Foundation and the Mastercard Foundation to launch a call for applications to establish innovative networks of research excellence in epidemic and pandemic sciences across Africa.
CEPI will provide up to $25 million to the University of Oxford to complete early development of prototype vaccines against the Jun\u00edn virus, with a new project led by Professor Teresa Lambe.
The RECOVERY trial, the leading global clinical trial of treatments for COVID-19, has expanded to find effective treatments for patients hospitalised with flu.
Research published today brings together for the first time the epidemiology and evolution of the SARS-CoV-2 virus in the UK during the first three years of the pandemic \u2013 including how variants emerged and spread.
The University of Oxford has launched a new global vaccine collaboration, backed by \u00a38 million funding from UK Research and Innovation (UKRI), and led by two PSI Principal Investigators.
The UK trial is the next step in the development of a vaccine to protect people against MERS \u2013 a deadly viral illness with no current vaccines and the potential to cause a pandemic.
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
![\"\"](\"https://www.psi.ox.ac.uk/news-and-opinion/study-explores-aerosol-immunisation-as-path-to-broadly-protective-influenza-vaccine/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n